Option chain shows key data for Lexaria Bioscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lexaria Bioscience.

Lexaria Bioscience (NASDAQ:LEXX) Stock, Option Chain

LEXARIA BIOSCIENCE CORP

Lexaria Bioscience

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Crude

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

COEP

COUR

LEXX

SAIA

Crude Oil Edges Higher; Phillips 66 Posts Wider-Than-Expected Loss

Portland,,Or,,Usa,-,Mar,12,,2020:,Dow,Jones,Index

Earnings

AGMH

AZUL

GOOG

GOOGL

OMEX

Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results

Movers

Pre-Market Outlook

ALBT

ANNX

BARK

CAPT

Core Scientific, Inc. - Class A Common Stock

CORZ

FGEN

MBOT

MLGO

NIVF

PLTN

SQNS

WIMI

YGMZ

Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Lexaria Bioscience Corp

Press Releases

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Offerings

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

LEXXW

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

TherapeuticsMD

VYNE Therapeutics

HC Wainwright & Co.

Maxim Group

Comments

Lexaria Bioscience

Lexaria Bioscience (LEXX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell